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Educational Objectives
Following this unit of instruction, the practitioner should be able to:
1. Understand the etiology and presentation of peri-implantitis.
2. Discuss different methods used to manage peri-implantitis.
3. Understand the limitations of surgical and non-surgical approaches used to manage 
peri-implantitis.
4.   Recognize the importance of searching the available literature to stay current with 
effective methods to manage peri-implantitis.
Introduction 
D ental implants are often offered as an option to replace missing natural teeth. The predictability of implants has led to increased popularity 
among both clinicians and patients over the past several 
decades. Implant placements worldwide have increased 
exponentially and are now estimated to be about 15 
million annually.1 Much attention has been given over the 
past decade to inflammatory pathology occurring around 
implants. Two types of peri-implant diseases have been 
identified: a) peri-implant mucositis - a reversible, 
inflammatory process in the peri-implant region presenting 
as reddening, swelling and bleeding on probing without 
loss of supporting bone,2 and; b) peri-implantitis - an 
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inflammatory process resulting in progressive loss of 
supporting bone around the implant (Figure 1).3 
There has been no consensus regarding clearly defined 
criteria for peri-implantitis, with at least thirteen different 
definitions being presented. There are also multiple different 
classifications of the disease. One of the classification 
systems (Froum and Rosen) classified peri-implantitis 
into three categories based on pocket depth and bone 
loss (Table 1).4 The reported prevalence of peri-implant 
mucositis is 43% with a range of 19-65%. Peri-implantitis 
prevalence is reported at 22% with a range of 1- 47.1%.5 
The enormous range in these estimates is due to varying 
case definitions, study designs and population sizes, as 
well as subjects with different risk profiles.
 Figure 1 
Clinical and radiographic appearance of Peri-implantitis with loss of supporting bone.
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Peri-implantitis demands aggressive management 
compared to peri-implant mucositis. Hence, 
this Quality Resource Guide will focus on 
peri-implantitis, its risk factors, prevention and 
management.
Risk Factors for 
Peri-implantitis
T here are a number of factors that have been implicated in the development of peri-implantitis; however, poor 
oral hygiene leading to the development of a 
pathogenic microbial biofilm or plaque is probably 
the most apparent concern in most of our 
patients.  Incomplete plaque removal around an 
implant can result initially in the development of 
peri-implant mucositis.6 Peri-implant mucositis 
represents the soft tissue inflammatory response 
to bacterial challenge by the microbial biofilm 
and is considered an important precursor for 
peri-implantitis.7 As we continue to enhance 
our understanding of the role for maturation of 
a pathogenic biofilm in developing periodontal 
disease, we are beginning to see evidence of 
similar biofilm development on implant surfaces.8 
Pre-existing peri-implant mucositis without 
maintenance significantly increases the incidence 
of peri-implantitis, demonstrating clinical 
consequences of a maturing pathogenic biofilm.9 
There appears to be a strong relationship between 
microbiota in periodontal disease, peri-implant 
disease and natural teeth. Natural teeth with 
periodontal disease appear to act as a reservoir 
for pathogens in partially edentulous patients 
putting implants in these patients at greater risk 
of peri-implantitis.10,11 Individuals with history of 
periodontitis demonstrate a higher incidence of 
peri-implantitis, with deeper probing depths and 
increase in marginal bone loss.12 Clinicians need to 
exert extra caution in the use of implant therapy for 
patients with a history of periodontal disease, and 
certainly in those patients with active periodontal 
disease around remaining natural teeth.13
With this well-established cause and effect 
relationship between poor oral hygiene and 
peri-implant disease, the role for a preventive 
maintenance program becomes critical to long-
term implant success. Often oral hygiene and 
maintenance therapy may be further compromised 
by complex prosthetic designs.  Where possible, 
both prosthetic designs and maintenance regimens 
should be adjusted with these factors in mind to 
enhance the possibility of long-term success.  
Apart from microbial biofilm accumulation, various 
other local and systemic factors have been 
implicated as risk factors that increase risk of 
peri-implantitis. Renvert and Quirynen examined 
the available evidence and listed the following as 
risk factors for peri-implantitis:14 
Local Factors
• Poor hygiene
• Smoking
• History of periodontitis
• Restorative cement overflow
• Occlusal overload
• Poor restoration design
Systemic Factors
• Diabetes
• Cardiovascular diseases 
Systematic reviews suggest peri-implantitis may 
occur in smokers about four times as often as 
non-smokers (odds ratios between 3.6-4.6).15,16 
Another important local factor associated with peri-
implantitis is retained cement. Cement overflow 
may occur during implant crown cementation and 
act as foreign body, triggering inflammation. Peri-
implantitis is seen in 85% of implants that exhibit 
incidental cement remnants.17 Implants with 
cemented restorations have 3.6 times more risk 
of peri-implantitis than those with screw retained 
restorations.18 Unfortunately, radiographs are 
unreliable in detecting excess cement and provide 
little evidence of cement overflow, increasing the 
need for careful clinical assessment.19 Occlusal 
overload remains controversial as a risk factor 
for peri-implantitis, with studies both supporting 
and refuting its role in leading to peri-implantitis. 
While occlusal overload remains questionable as 
a causative agent, care should be given to assure 
that it is minimized.20 
Peri-implantitis is most prevalent in mandibular 
posterior regions and least prevalent in the 
maxillary anterior region.18 Implants placed in the 
maxilla have shown a rate of failure three times 
higher than those placed in the mandible.21 This 
has been attributed to the poorer bone quality 
in maxilla, especially in posterior regions.22 The 
bone type at specific sites may also play a role 
in success of implant. All bone types, except 
type 2*, have reported almost two times greater 
risk for early implant failure,23 and type 4 bone* 
has shown the greatest failure rate (63%).24
*  Type 1 bone: almost the entire bone is composed 
of homogenous compact bone 
 Type 2 bone: a thick layer of compact bone 
surrounds a core of dense trabecular bone
 Type 3 bone: a thin layer of cortical bone 
surrounds a core of dense trabecular bone
 Type 4 bone: a thin layer of cortical bone 
surrounds a core of low-density trabecular bone
 Table 1 - Classification of Perio-Implantitis4
Early PD
A > 4mm (bleeding and/or suppuration on probing)B
Bone loss <25% of implant lengthC 
Moderate probing depth > 6mm (bleeding and/or suppuration on probing)
B
Bone loss 25-50% of implant lengthC
Severe probing depth > 8mm (bleeding and/or suppuration on probing)
B
Bone loss >50% of implant lengthC 
A Probing Depth
B Noted on two or more aspects of the implant. 
C Measured on radiographs from the time of definitive prosthesis loading to current radiograph.  
If not available, the earliest available radiograph following loading should be used.
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Apart from local factors, systemic conditions may 
also play a role in progression of peri-implantitis. 
In the past, some have stated that implants were 
contraindicated in diabetic patients.25 However, in 
the recent years, implants have been successfully 
placed in patients with poorly controlled diabetes.26 
When comparing the clinical outcomes between 
well and poorly controlled diabetics, little difference 
was noted in prevalence rate of bleeding on probing, 
however, the prevalence of bone loss was higher 
in the poorly controlled group (60% vs. 45%).27 
Retrospective analysis reported cardiovascular 
disease as a risk factor for peri-implantitis (odds 
ratio 8.7) and a high likelihood of comorbidity.6 One 
of the study’s limitations was that cardiovascular 
disease was self-reported, reducing the reliability 
of the reported data. Overall, there is limited 
data demonstrating that cardiovascular disease 
affects bone loss. Other systemic factors, such 
as osteoporosis and radiation therapy in head 
and neck region, can affect osseointegration and 
are considered as contraindications to implant 
placement. 
Due to multifactorial peri-implant disease model, 
one should be mindful of possible correlation of 
local and systemic factors. Biofilm is considered 
as the primary offending factor responsible for 
marginal bone loss. Hence, it is important to 
establish an implant maintenance program that 
is designed based upon the patient’s difficulty in 
consistently removing plaque from the implant 
region and the presence of other risk factors. It 
should be adjusted as necessary.
Diagnostic Criteria for  
Peri-implantitis 
E arly detection of peri-implant mucositis progression results in better case management and an increased chance 
of implant survival. Peri-implant mucositis is a 
reversible process. Control of local factors can help 
improve clinical parameters and halt progression to 
irreversible peri-implantitis. 
Important diagnostic criteria for peri-implantitis 
are bleeding and/or suppuration on probing, 
with progressively increasing probing depths. 
It is extremely important to probe the implant 
region initially to establish a baseline, and then 
at each maintenance visit to detect any increases 
in probing depths. As anatomic factors associated 
with differing implant designs may greatly alter 
what would be considered normal probing depths 
in that specific circumstance, the identification of 
a change from baseline probing depth serves as a 
critical indicator. Healthy sulcular depths may vary 
because of differences in implant systems, depth of 
abutments, positioning of implant margins relative 
to adjacent bone levels, as well as surgical and 
loading protocols.28 Using a reference point on the 
restoration, probing depth is measured from the 
base of the implant sulcus to the crest of gingival 
margin.29 The clinician must remember that the soft 
tissue attachment to the implant differs from that to 
natural teeth; lighter probing is encouraged around 
dental implants than around teeth.30 There is no 
evidence that the type of probe (metal or plastic) 
affects probing depth assessment or has any clinical 
impact on the implant surface.  It is more critical to 
obtain accuracy in probing than be concerned about 
potential impact to the implant surface. It is also 
important to consider changes in probing depths 
as a consequence of marginal tissue inflammation 
rather than bone loss.  Given the altered soft tissue 
attachment to the implant surface, inflammation 
in these tissues creates greater disruption of the 
tissue integrity and may allow the probe tip to 
penetrate to the bone crest.31 Therefore, critical 
appraisal of the probing needs to consider the 
baseline measurements were most likely made in 
the absence of inflammation. Alterations in probing 
depths need to be considered relative to the level 
of inflammation present, knowing that the latter 
circumstance may better reflect the position of the 
bone crest.
Treatment of  
Peri-implantitis
B oth surgical and non-surgical approaches have been evaluated for the management of peri-implantitis. The treatment approach 
employed is determined by probing depth and 
defect characteristics. A non-surgical approach 
involves surface detoxification using mechanical, 
chemical, lasers and antibiotic therapy (locally and/
or systemically). Surgical approaches include access 
flap, as well as resective and regenerative surgical 
techniques. 
Non-Surgical Approaches 
Implant surface detoxification is a common step 
for both surgical and non-surgical approaches. 
The goal of detoxification is to reduce the bacterial 
load on the implant surface and render it free 
of bacterial by-products. Often, detoxification is 
accomplished using periodontal curettes. Curettes 
used for debridement of the implant surface must 
be softer than the material comprising the implant. 
Traditional stainless steel curettes have higher 
external hardness than titanium and will result in 
scratches on the implant surface. They should not 
be used on titanium implants, however they can be 
safely employed if the implant is made of titanium 
zirconoxide or titanium oxinitride.32 Titanium-coated 
curettes are similar in hardness to titanium implants 
and minimize scratching of the implant surface.33 
Non-metal curettes can successfully remove 
biofilm from implant and abutment surfaces, and 
are recommended for titanium implants.34 They are 
available as plastic, carbon, resin-reinforced and 
resin-unreinforced. Ultrasonic scalers may also be 
used to detoxify the implant surface. An ultrasonic 
scaler with a metal tip has been shown to eliminate 
bacteria and irregularities from an implant surface 
more efficiently than one using a plastic tip. Also, 
use of the plastic tip resulted in same surface 
irregularities as using the metal tip.35 
Air-powder abrasive polishing has been shown 
to be effective in biofilm removal from an implant 
surface. Air abrasives containing glycine powder, as 
opposed to those comprised of sodium bicarbonate 
powder, are recommended due to effective biofilm 
removal without any damaging effects on hard and 
soft tissues.36 Detoxification of the implant surface 
may also be achieved with application of hydrogen 
peroxide, EDTA, chlorhexidine, citric acid, saline 
or the local application of antibiotics. Soaking an 
implant surface with 3% hydrogen peroxide for 
one minute demonstrated inactivation of attached 
bacteria.37 
Following surface detoxification, local delivery 
system using chips were evaluated. Bone 
matrix chips (MatrixC) and chlorhexidine chips 
(PerioC) were compared for six months in sixty 
patients. Following the therapy, patients with 
initially deeper probing depth showed a reduction of 
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2mm in the PerioC group and 1.59mm in MatrixC 
group. Minocycline spheres and chlorhexidine 
gel debridement were compared for a year and 
showed improvement in plaque indices, pocket 
depths and bleeding. Minocycline was shown to 
be effective but to maintain the effectiveness, 
additional applications might be needed.38,39 Use 
of chlorhexidine in humans has been shown to 
decrease cell proliferation and reduce collagen 
synthesis,40 hence its use in implant surface 
detoxification is questioned. 
The applications of dental lasers for dental therapy 
continue to grow. Laser therapy has been suggested 
for management of peri-implantitis due to its anti-
infective and ablative properties. Currently lasers 
available in the market are: Nd:Yag; carbondioxide; 
diode, and Er:Yag. Er:Yag is considered to have the 
most potential for management of peri-implantitis. 
Along with effective plaque removal, Er:Yag is 
not absorbed by the titanium surface and its use 
of water irrigation prevents overheating of bone. 
Recommended setting for the laser is 100mJ at a 
frequency of 10Hz for 2 minutes. Higher settings 
can cause implant surface changes.41 Comparative 
studies evaluating use of Er:Yag alone in comparison 
to surgical and nonsurgical therapy for peri-
implantitis did not show any additional benefits of 
lasers.42  Photodynamic therapy, utilizing 630-700nm 
wavelength of light, has shown reduction in clinical 
disease parameters for up to six months combined 
with application of minocycline.42
Implantoplasty (reshaping and/or smoothing the 
implant surface) may be completed with a combination 
of diamond and carborundum burs, or carborundum 
burs alone.34 The goal of implantoplasty is a smooth 
implant surface that enables better maintenance by 
the patient and/or the clinician. Implantoplasty may 
result in soft tissue loss, creating esthetic concerns 
and potentially leading to increased food impaction 
in interproximal spaces. Implantoplasty requires 
minimal implant surface removal hence implant 
weakening does not appear to be an issue. The risks 
and benefits of the procedure should be thoroughly 
discussed with the patient, explaining the potential 
adverse and irreversible outcomes. There is limited 
evidence supporting its application and it should 
only be employed as an adjunct to other therapeutic 
measures. 
Surgical Approaches
A nonsurgical approach is recommended in 
shallow defects to maintain the height of the soft 
tissue margins.44 Non-surgical therapies, however, 
may offer limited access in some regions and 
surgical therapy may be necessary to enhance 
the opportunity for long-term stabilization. The 
surgical technique employed depends on defect 
morphology and typically involves an access 
flap and debridement/detoxification, followed by 
resective and/or regenerative procedures. Schwarz 
et al. demonstrated that a combination of resective 
and regenerative surgical techniques are usually 
more effective.45 Defect morphology can impact the 
treatment outcome following regenerative therapy.46
The objective of an access flap and debridement is 
to remove the inflamed tissue around the implant, 
allowing access to the osseous defect. Implant 
surface detoxification, as discussed earlier, can 
be achieved using chemical, mechanical and/or 
lasers following tissue reflection. In non-esthetic 
regions with a shallow, one-walled intrabony defect, 
effective therapy consists of implantoplasty and 
osteoplasty followed by apically repositioning of the 
soft tissue flap. This will result in tissue recession 
and a region more conducive to successful 
maintenance. 
Multiple studies have reported various surgical 
approaches based on defect morphology, irrigants, 
employing single or multiple grafting materials and, 
use of resorbable or non-resorbable membrane. 
There is no single surgical therapy that is considered 
superior over other.  Surgical therapy includes 
elevation of mucoperiosteal flap, access to implant 
surface and defect by removal of granulation tissue, 
implant surface decontamination or modification, 
resective or regenerative therapy and post-therapy 
systemic antibiotic administration.47 Implant removal 
should be considered if they are mobile with 
radiographic bone loss extending around the apex. 
As surgical therapies are complex procedures, it 
is highly recommended that they be performed by 
skilled clinicians with surgical training in periodontal 
therapies. Also, with no clear evidence supporting 
one specific therapy, literature should be reviewed 
consistently for strong evidence to support surgical 
approaches. 
Conclusion
A number of therapy approaches have demonstrated the potential to successfully treat 
peri-implantitis (Table 2). Techniques for 
the management of peri-implantitis are 
still evolving. Many protocols have been 
tried, with some showing promising clinical 
results. However, there is no protocol 
proven to be superior over other. At this 
time, it appears that research supports the 
following conclusions: 
1. Peri-implant mucositis acts as a 
precursor for peri-implantitis
2. Surface detoxification, along with 
modification of the implant and the 
tissue architecture to facilitate 
maintenance, are the most important 
steps in management of all peri-
implantitis lesions.
3. Lasers do not demonstrate additional 
benefit over other detoxification 
techniques. 
4. Defect morphology dictates type of 
surgical approach that should be 
utilized. 
 Table 2 - Therapeutic Options
Non-Surgical Surgical
• Surface 
detoxification
• Curettes
• Airpowder abrasive
• Local drug delivery 
• Lasers 
• Implantoplasty
• Resective 
• Regenerative 
• Combination
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 1. Peri-implantitis differs from peri-implant mucositis by 
a. Deep probing depths 
b. Bleeding on probing 
c. Loss of supporting bone
d. Swelling around restored implant
 2. Identify least potential risk factors in the etiology of 
peri-implantitis could be all of the following, EXCEPT:
a. A screw retained implant crown
b. Diabetes 
c. Poor oral hygiene 
d. Occlusal overload
 3. Surface detoxification is common step for surgical and 
non-surgical approaches for treating peri-implantitis.
a. True
b. False
 4. Implants should be managed for peri-implantitis in all 
of the cases, EXCEPT:
a. Near anatomic landmark
b. Key restorative position
c. Intrabony defects 
d. Mobility
 5. All of the following are true about implantoplasty, 
EXCEPT:
a. Compromises esthetics 
b. Enables maintenance
c. Stimulates re-osseointegration
d. Results in soft tissue loss
 6. Selection of a peri-implantitis treatment approach 
depends on:
a. Defect morphology 
b. Probing depth 
c. Radiographic bone loss in relation to implant length 
d. All of the abov
 7. During surgical management of peri-implantitis, 
implants must be always submerged.
a. True
b. False
 8. The proposed Er:Yag laser setting for peri-implantitis 
management is:
a. 100mJ/10Hz
b. 50mJ/15Hz 
c. 120mJ/10Hz 
d. 100mJ/20Hz
 9. In a defect with less than 4mm probing depth, bleeding 
on probing, 10-15% bone loss along the implant 
length and systemically healthy patient, the following 
is approach to treating peri-implantitis would be 
generally recommended:
a. Surgical approach 
b. Non-surgical approach
c. Combination of surgical and non-surgical therapy
d. No treatment 
 10. Access flaps allow:
a. Removal of inflamed tissue around the implant 
b. Access to peri-implantitis defect
c. All of the above
d. None of the above 
POST-TEST
Internet Users: This page is intended to assist you in fast and accurate testing when completing the “Online Exam.”  
We suggest reviewing the questions and then circling your answers on this page prior to completing the online exam. 
(1.0 CE Credit Contact Hour) Please circle the correct answer. 70% equals passing grade.
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Providing dentists with the opportunity for continuing dental education is an essential part of MetLife’s commitment to helping dentists improve the oral health of 
their patients through education.  You can help in this  effort by providing feedback regarding the continuing education offering you have just completed.
MetLife Dental Quality Initiatives Program
501 US Highway 22
Bridgewater, NJ 08807
To Complete Program Traditionally, Please Mail Your Post Test and Evaluation Forms To:
FOR
OFFICE
USE 
ONLY
REGISTRATION/CERTIFICATION INFORMATION (Necessary for proper certification)
Name (Last, First, Middle Initial): __________________________________________________________________
Street Address: _____________________________________________________  Suite/Apt. Number _________
City:  ______________________________________   State: _______________   Zip: _____________________
Telephone:  _______________________________________ Fax: ______________________________________
Date of Birth: ______________________________________ Email:  ____________________________________
State(s) of Licensure: _______________________________ License Number(s): __________________________
Preferred Dentist Program ID Number: _____________________________   Check Box If Not A PDP Member
AGD Mastership:  Yes  No 
AGD Fellowship:   Yes  No   Date: ______________
Please Check One:   General Practitioner  Specialist  Dental Hygienist  Other
PLEASE PRINT CLEARLY
www.metdental.com
Please respond to the statements below by checking the appropriate box,  1 = POOR    5 = Excellent 
using the scale on the right. 1 2 3 4 5
 1. How well did this course meet its stated educational objectives?     
2. How would you rate the quality of the content?     
3. Please rate the effectiveness of the author.     
4. Please rate the written materials and visual aids used.     
5. The use of evidence-based dentistry on the topic when applicable.        N/A
 6. How relevant was the course material to your practice?     
7. The extent to which the course enhanced your current knowledge or skill?     
 8. The level to which your personal objectives were satisfied.     
 9. Please rate the administrative arrangements for this course.     
Thank you for your time and feedback.
10.  How likely are you to recommend MetLife’s CE program to a friend or colleague? (please circle one number below:)
           10          9          8          7          6          5          4          3          2          1          0
      extremely likely                     neutral                                        not likely at all
       What is the primary reason for your 0-10 recommendation rating above?
 
11.   Please identify future topics that you would like to see:
 
